KRAS and BRAF mutations in prostate carcinomas of Chinese patients

Cancer Genetics and Cytogenetics

Volumn 198, Issue 1, 2010, Pages 35-39

  Shen, Yanying ^a   Lu, Yachao ^b   Yin, Xiaolu ^b   Zhu, Guanshan ^b   Zhu, Jianshan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYSTEINE; GLYCINE; K RAS PROTEIN; VALINE; BRAF PROTEIN, HUMAN;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER STAGING; CARCINOGENESIS; CHINA; CLINICAL FEATURE; CODON; CONTROLLED STUDY; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR DIFFERENTIATION; ASIAN; GENETICS; MIDDLE AGED; MUTATION; ONCOGENE RAS; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 77950360748     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.12.003     Document Type: Article

References (32)

1. Eble J.N., Sauter G., Epstein J.I., Sesterhenn I.A. Pathology and genetics tumours of the urinary system and male genital organs 2004, IARC Press, Lyon.
2. Immervoll H., Hoem D., Kugarajh K., Steine S.J., Molven A. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch 2006, 448:788-796.
3. Haigis K.M., Kendall K.R., Wang Y., Cheung A., Haigis M.C., Glickman J.N., Niwa-Kawakita M., Sweet-Cordero A., Sebolt-Leopold J., Shannon K.M., Settleman J., Giovannini M., Jacks T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008, 40:600-608.
4. Fukushima T., Takenoshita S. Roles of RAS and BRAF mutations in thyroid carcinogenesis. Fukushima J Med Sci 2005, 51:67-75.
5. Gruber F., Kastelan M., Brajac I., Saftić M., Peharda V., Cabrijan L., Stanić Zgombić Z., Simonić E. Molecular and genetic mechanisms in melanoma. Coll Antropol 2008, 32:147-152.
6. Fransén K., Klintenäs M., Osterström A., Dimberg J., Monstein H.J., Söderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004, 25:527-533.
7. Bakin R.E., Gioeli D., Sikes R.A., Bissonette E.A., Weber M.J. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003, 63:1981-1989.
8. Bakin R.E., Gioeli D., Bissonette E.A., Weber M.J. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 2003, 63:1975-1980.
9. Jeong J.H., Wang Z., Guimaraes A.S., Ouyang X., Figueiredo J.L., Ding Z., Jiang S., Guney I., Kang G.H., Shin E., Hahn W.C., Loda M.F., Abate-Shen C., Weissleder R., Chin L. BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One 2008, 3:e3949.
10. Gioeli D., Mandell J.W., Petroni G.R., Frierson H.F., Weber M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999, 59:279-284.
11. Konishi N., Hiasa Y., Tsuzuki T., Tao M., Enomoto T., Miller G.J. Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate 1997, 30:53-57.
12. Anwar K., Nakakuki K., Shiraishi T., Naiki H., Yatani R., Inuzuka M. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 1992 Nov 1, 52(21):5991-5996.
13. Suzuki H., Aida S., Akimoto S., Igarashi T., Yatani R., Shimazaki J. State of adenomatous polyposis coli gene and ras oncogenes in Japanese prostate cancer. Jpn J Cancer Res 1994, 85:847-852.
14. Shiraishi T., Muneyuki T., Fukutome K., Ito H., Kotake T., Watanabe M., Yatani R. Mutations of ras genes are relatively frequent in Japanese prostate cancers: pointing to genetic differences between populations. Anticancer Res 1998, 18:2789-2792.
15. Konishi N., Hiasa Y., Matsuda H., Tao M., Tsuzuki T., Hayashi I., Kitahori Y., Shiraishi T., Yatani R., Shimazaki J. Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am J Pathol 1995, 147:1112-1122.
16. Cho N.Y., Choi M., Kim B.H., Cho Y.M., Moon K.C., Kang G.H. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer 2006, 119:1858-1862.
17. Moyret-Lalle C., Marçais C., Jacquemier J., Moles J.P., Daver A., Soret J.Y., Jeanteur P., Ozturk M., Theillet C. Ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 1995, 64:124-129.
18. Liu T., Willmore-Payne C., Layfield L.J., Holden J.A. Lack of BRAF activating mutations in prostate adenocarcinoma: a study of 93 cases. Appl Immunohistochem Mol Morphol 2009, 17:121-125.
19. Burger M., Denzinger S., Hammerschmied C., Tannapfel A., Maderstorfer A., Wieland W.F., Hartmann A., Stoehr R. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations. Eur Urol 2006, 50:1102-1109.
20. Kim K.H., Suh K.S., Kang D.W., Kang D.Y. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol Int 2005, 55:540-545.
21. Kim K.H., Kang D.W., Kim S.H., Seong I.O., Kang D.Y. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004, 45:818-821.
22. Kim T.Y., Kim W.B., Rhee Y.S., Song J.Y., Kim J.M., Gong G., Lee S., Kim S.Y., Kim S.C., Hong S.J., Shong Y.K. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006, 65:364-368.
23. Liu R.T., Chen Y.J., Chou F.F., Li C.L., Wu W.L., Tsai P.C., Huang C.C., Cheng J.T. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 2005, 63:461-466.
24. Nakayama H., Yoshida A., Nakamura Y., Hayashi H., Miyagi Y., Wada N., Rino Y., Masuda M., Imada T. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 2007, 27:3645-3649.
25. Fugazzola L., Mannavola D., Cirello V., Vannucchi G., Muzza M., Vicentini L., Beck-Peccoz P. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004, 61:239-243.
26. Asaka S., Arai Y., Nishimura Y., Yamaguchi K., Ishikubo T., Yatsuoka T., Tanaka Y., Akagi K. Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B. Carcinogenesis 2009, 30:494-499.
27. Lee S., Cho N.Y., Choi M., Yoo E.J., Kim J.H., Kang G.H. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int 2008, 5:104-113.
28. Park H.W., Kang H.C., Kim I.J., Jang S.G., Kim K., Yoon H.J., Jeong S.Y., Park J.G. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. Int J Cancer 2007, 1(120):7-12.
29. Chang S.C., Lin J.K., Yang S.H., Wang H.S., Li A.F., Chi C.W. Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer 2006, 1(118):1721-1727.
30. Yuen S.T., Davies H., Chan T.L., Ho J.W., Bignell G.R., Cox C., Stephens P., Edkins S., Tsui W.W., Chan A.S., Futreal P.A., Stratton M.R., Wooster R., Leung S.Y. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002, 62:6451-6455.
31. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934.
32. Bouali S., Chrétien A.S., Ramacci C., Rouyer M., Becuwe P., Merlin J.L. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Oncol Rep 2009, 21:731-735.